Peoples Financial Services CORP. Has $3.34 Million Holdings in Pfizer Inc. (NYSE:PFE)

Peoples Financial Services CORP. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 1.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 91,037 shares of the biopharmaceutical company’s stock after selling 1,555 shares during the quarter. Pfizer accounts for approximately 1.5% of Peoples Financial Services CORP.’s investment portfolio, making the stock its 15th biggest position. Peoples Financial Services CORP.’s holdings in Pfizer were worth $3,339,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Moneta Group Investment Advisors LLC raised its holdings in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the last quarter. Norges Bank acquired a new position in Pfizer in the fourth quarter valued at $3,150,472,000. Wellington Management Group LLP grew its holdings in Pfizer by 9.8% during the 1st quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock worth $8,932,423,000 after acquiring an additional 19,602,359 shares during the period. Renaissance Technologies LLC raised its position in shares of Pfizer by 1,034.0% in the 1st quarter. Renaissance Technologies LLC now owns 12,149,955 shares of the biopharmaceutical company’s stock worth $495,718,000 after acquiring an additional 11,078,514 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 14.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,901,181 shares of the biopharmaceutical company’s stock valued at $3,408,836,000 after purchasing an additional 10,560,702 shares in the last quarter. Institutional investors and hedge funds own 68.05% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Morgan Stanley dropped their price target on Pfizer from $42.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 2nd. BMO Capital Markets dropped their price objective on shares of Pfizer from $45.00 to $44.00 and set an “outperform” rating on the stock in a report on Wednesday, August 2nd. Barclays reduced their target price on Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. Jefferies Financial Group reduced their price objective on Pfizer from $40.00 to $38.00 in a research note on Wednesday, August 2nd. Finally, HSBC began coverage on Pfizer in a report on Friday, July 14th. They issued a “buy” rating and a $50.00 target price on the stock. Twelve investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $46.35.

Pfizer Stock Down 0.2 %

Shares of NYSE:PFE opened at $34.07 on Monday. The company has a market cap of $192.36 billion, a price-to-earnings ratio of 9.06, a PEG ratio of 1.14 and a beta of 0.59. Pfizer Inc. has a one year low of $33.54 and a one year high of $54.93. The firm has a fifty day moving average price of $35.80 and a two-hundred day moving average price of $37.96. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 1.82.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.10. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The company’s revenue for the quarter was down 54.1% on a year-over-year basis. During the same quarter last year, the company posted $2.04 EPS. Analysts anticipate that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th were given a dividend of $0.41 per share. The ex-dividend date was Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.81%. Pfizer’s dividend payout ratio (DPR) is presently 43.62%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.